Verici Dx plc (AIM:VRCI)

Market Cap	7.94M -16.0%
Revenue (ttm)	2.65M +84.1%
Net Income	-5.94M
EPS	-0.00
Shares Out	3.97B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,905,375
Open	0.2000
Previous Close	0.2050
Day's Range	0.2000 - 0.2100
52-Week Range	0.1943 - 0.9800
Beta	1.18
Analysts	n/a
Price Target	n/a
Est. Earnings	May 28, 2027

About Verici Dx

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 23
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VRCI

Financial Performance

In 2025, Verici Dx's revenue was $3.66 million, an increase of 9.73% compared to the previous year's $3.34 million. Losses were -$6.93 million, 18.0% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error